Semax

Overview

Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro, designed as an analog of adrenocorticotropic hormone (ACTH) fragment 4-10. Specifically, Semax represents ACTH(4-7) with an extended C-terminal Pro-Gly-Pro tripeptide tail designed to enhance enzymatic stability and plasma half-life. The peptide was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, the same research institution that developed Selank and other investigational peptides.

Semax was approved in Russia in 2011 and is licensed for treatment of acute ischemic stroke, chronic cerebrovascular disorders, cognitive enhancement, and attention deficit disorders in Russian clinical practice. Unlike Selank (which is anxiolytic), Semax is characterized as a "nootropic" or "activating" peptide that enhances cognitive function, learning capacity, and memory without producing sedation or anxiety reduction. The peptide's primary mechanisms center on upregulation of growth-promoting factors (BDNF and NGF) that support neuroplasticity, neuronal survival, and synaptic function.

A critical distinction between Semax and traditional ACTH is that Semax, despite its ACTH-derived structure, does not stimulate adrenal cortex function or produce hormonal side effects characteristic of ACTH. This represents a major advantage over ACTH itself, as the nootropic benefits are decoupled from systemic hormonal effects. Semax remains unapproved by the FDA and has not undergone clinical trials in the United States.

FDA and Regulatory Status

As of April 2026:

• NOT FDA-approved for any indication in the United States
• Approved in Russia (2011) for acute stroke, cognitive disorders, ADHD, and traumatic brain injury
• No IND application or clinical trials in U.S.. No FDA development program exists
• Limited availability outside Russia: Available in some Eastern European and CIS countries
• Not approved in Europe (EMA), UK, Canada, Australia, or other major regulatory jurisdictions

Semax's regulatory position is similar to Selank in that approval is limited to Russia, though the clinical indications differ (Semax: neuro/cognitive; Selank: psychiatric/anxiety).

Mechanism of Action

Semax's mechanisms of action are distinctly neuroprotective and neuroplasticity-supporting, centered on upregulation of growth factors and enhancement of neuronal function:

1. Brain-Derived Neurotrophic Factor (BDNF) Upregulation

The primary and most extensively documented mechanism of Semax involves upregulation of brain-derived neurotrophic factor (BDNF) expression in the brain. BDNF is a critical growth factor essential for neuronal survival, growth, synaptic plasticity, and learning/memory formation. Published research has demonstrated that Semax administration increases BDNF levels in multiple brain regions following both acute and chronic dosing. Enhanced BDNF expression supports neuronal health, promotes synaptic strength, facilitates long-term potentiation (the cellular basis of learning), and may support recovery following neuronal injury. This BDNF-enhancing mechanism is considered fundamental to Semax's nootropic and neuroprotective effects.

2. Nerve Growth Factor (NGF) Enhancement

In addition to BDNF, Semax promotes nerve growth factor (NGF) expression, another critical growth factor supporting neuronal growth, survival, and function. NGF is particularly important for peripheral nerve function and central cholinergic neuronal systems. Enhanced NGF may contribute to recovery in neurodegenerative processes and traumatic neuronal injury.

3. Neuroplasticity and Synaptic Function Enhancement

By enhancing BDNF and NGF, Semax promotes neuroplasticity-the brain's capacity to form new neural connections and reorganize existing networks. This mechanism is particularly relevant to stroke recovery (where brain reorganization around damaged regions is critical for functional recovery) and to cognitive enhancement (where enhanced neuroplasticity facilitates learning and memory formation). The promotion of long-term potentiation (LTP) and long-term depression (LTD), the cellular mechanisms underlying learning and memory, represents a core mechanism by which Semax enhances cognitive function.

4. Dopamine and Monoamine System Modulation

Semax modulates dopaminergic neurotransmission, potentially enhancing dopamine availability and receptor signaling. This may contribute to cognitive enhancement (dopamine supports attention, motivation, and executive function), mood support, and potential benefits in ADHD and Parkinson's disease-related cognitive decline. The mechanism may involve both increased dopamine synthesis and modulation of dopamine receptor sensitivity.

5. Neuroprotection Against Ischemic and Excitotoxic Injury

In stroke and ischemic injury models, Semax has demonstrated neuroprotective effects, reducing infarct volume, mitigating inflammatory responses, and supporting neuronal survival. The mechanisms proposed include BDNF-mediated cell survival signaling, reduced excitotoxicity (reducing excessive glutamate-mediated neuronal damage), antioxidant effects, and modulation of apoptosis (programmed cell death). These neuroprotective mechanisms make Semax particularly relevant to stroke recovery applications.

6. Absence of Adrenal Stimulation Despite ACTH Origin

Unlike full-length ACTH, which strongly stimulates adrenocorticotropic hormone-mediated cortisol release, Semax does not activate adrenal function. The ACTH(4-7) fragment lacks the portion of ACTH required for ACTH receptor (melanocortin 2 receptor) activation in the adrenal cortex. This is a critical distinction, as it allows Semax to produce nootropic effects without the systemic hormonal effects and complications that would result from ACTH administration. This makes Semax applicable for chronic neuroprotective therapy without the need for adrenal monitoring or concern about cortisol dysregulation.

Common Research Applications

Acute Ischemic Stroke Recovery

The primary approved indication for Semax in Russia is acute ischemic stroke. The approved use involves administration of Semax early after stroke onset, with the mechanism involving neuroprotection of at-risk tissue (penumbra), reduction of infarct volume, and support for neuroplasticity-mediated recovery. Clinical trials conducted in Russia have examined Semax administered intravenously in acute stroke settings, with protocols typically involving high-dose early administration followed by ongoing therapy. Studies have reported improvements in stroke outcomes and functional recovery in Semax-treated patients compared to standard care controls.

Chronic Cerebrovascular Disorder and Post-Stroke Cognitive Impairment

Semax is approved for chronic treatment of cerebrovascular disorders, including post-stroke cognitive impairment and vascular dementia. The mechanism involves ongoing neuroprotection, BDNF support for neuroplasticity and recovery of function, and enhancement of cognitive reserve. Intranasal administration (the approved route for chronic use) provides ongoing cognitive support in patients with chronic cerebrovascular disease.

Cognitive Enhancement and Nootropic Application

Semax has been extensively studied as a cognitive enhancer in healthy populations and in those with cognitive decline. The BDNF upregulation and neuroplasticity-promoting mechanisms support enhanced learning, memory formation, and cognitive function. Russian research has examined Semax in students, professionals in high-cognitive-demand occupations, and aging populations seeking cognitive support. The mechanism involves supporting the neurobiological basis of learning and memory rather than producing stimulant effects as traditional cognitive enhancers (like amphetamines) would.

Attention Deficit Hyperactivity Disorder (ADHD)

ADHD is an approved indication for Semax in Russia, based on dopaminergic modulation, attention-enhancing mechanisms, and potential benefits in executive function. Clinical research in Russian pediatric and adult ADHD populations has examined Semax as a cognitive and attention enhancer. The mechanism involves enhancing dopaminergic systems involved in attention, motivation, and executive function without the potential for abuse or dependence characteristic of traditional ADHD stimulant medications.

Traumatic Brain Injury (TBI) Recovery

Semax has been investigated for supporting recovery following traumatic brain injury, based on neuroprotective mechanisms and BDNF-mediated promotion of neuroplasticity and neuronal regeneration. The rationale involves supporting the post-TBI neurobiological recovery process and potentially improving functional outcomes following brain trauma.

Age-Related Cognitive Decline and Neurodegeneration

Semax has been studied in aging populations and in early neurodegenerative disease contexts (Parkinson's disease, mild cognitive impairment, age-related memory decline), based on BDNF support for neuronal health and potential neuroprotective effects against neurodegenerative processes. While not a disease-modifying therapy for established neurodegenerative disease, Semax may support cognitive function and neuronal health in aging.

Depression and Mood Disorders

Some research has examined Semax for depression and mood support, based on dopaminergic and BDNF mechanisms (both implicated in depression pathophysiology). While Selank is more directly anxiolytic, Semax's mood-supporting properties may provide benefit in depression through different mechanisms (growth factor and dopamine support rather than GABA modulation).

Studied Benefits and Clinical Evidence

Important caveat: Published clinical evidence for Semax derives from Russian clinical trials and research. Evidence quality and extent is more substantial than preclinical-only compounds but less extensive than typical FDA-regulated pharmaceutical development. All published clinical evidence originates from Russian sources; there are no published U.S. clinical trials.

Stroke Recovery and Functional Outcome Improvement

Multiple Russian clinical trials examining Semax in acute stroke settings have reported improved outcomes in stroke recovery. Studies have documented reduced infarct volumes (measured by imaging), faster recovery of neurological function (as measured by stroke scales like NIHSS), and improved functional independence at discharge and follow-up. A landmark study published by a Russian stroke research group demonstrated that Semax administered intravenously in acute stroke significantly reduced disability at 3-month follow-up compared to standard care alone. The mechanism involves both acute neuroprotection and support for ongoing neuroplasticity-mediated recovery.

Cognitive Enhancement in Healthy Populations

Russian research examining Semax in healthy adults and students has reported improvements in cognitive function including verbal learning, memory consolidation, and information processing speed. Published studies employing neuropsychological testing batteries have demonstrated statistically significant improvements in specific cognitive domains (working memory, verbal fluency, attention) in Semax-treated groups compared to controls. These effects are attributed to BDNF-mediated enhancement of synaptic plasticity and the neurobiological basis of learning and memory.

Attention and Executive Function Improvement

Clinical research in ADHD and in populations with attention disorders has reported that Semax improves attention, concentration, and executive function. Studies have employed continuous performance tests and other attention-specific neuropsychological measures documenting significant improvements in Semax-treated groups. The mechanism involves dopaminergic modulation and BDNF enhancement of prefrontal cortex function, critical to executive function and attention regulation.

Safety and Tolerability

Across multiple Russian clinical trials and post-marketing surveillance, Semax is reported to be well-tolerated with minimal adverse effects. The reported safety profile has supported its regulatory approval in Russia and continuing clinical use. Importantly, unlike ACTH, Semax does not produce adrenal activation, cortisol elevation, or hormonal side effects, which represents a significant safety advantage. Reported adverse effects are minimal and primarily limited to occasional mild nasal irritation (intranasal route) or rare mild headache.

Long-Term Safety Data

Post-marketing surveillance data from Russia provides experience with long-term Semax use in chronic stroke and cognitive disorder populations, some receiving Semax for months to years. This long-term safety data has been accumulated through clinical practice experience and supports that Semax can be used chronically without documented accumulation of adverse effects or serious complications.

Dosing and Administration

Acute Stroke Dosing

For acute ischemic stroke, Semax is administered intravenously in high doses: typically 500 mcg to 1,000 mcg (1 mg) administered twice daily for the acute phase (typically 3-7 days), with the rationale being high-dose early treatment to maximize neuroprotection and reduce infarct volume. Some protocols employ even higher doses (up to 1.5-2 mg per administration) in the acute setting. Following acute phase treatment, many protocols transition to intranasal maintenance therapy.

Chronic/Maintenance Dosing (Intranasal)

For chronic use in post-stroke cognitive impairment, cognitive disorders, ADHD, and other chronic indications, Semax is administered as intranasal spray at doses of 200-600 mcg daily, typically divided into one or two administrations. Some protocols employ 300 mcg once daily, while others use 300-600 mcg daily in divided doses. Treatment duration in clinical protocols varies from weeks (for acute cognitive support) to months or years (for chronic neuroprotection and cognitive enhancement).

Subcutaneous Administration (Research Contexts)

In research contexts and some clinical settings, Semax has been administered subcutaneously at doses ranging from 100-500 mcg per dose, typically administered once or twice daily. Subcutaneous doses are generally lower than intranasal doses, presumably due to different pharmacokinetics and potential for higher tissue concentration from intranasal delivery.

Bioavailability and CNS Penetration

Intranasal administration allows direct central nervous system delivery via olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier and potentially achieving higher brain concentrations than systemic administration. This intranasal route is the standard chronic formulation in Russia and is believed to optimize CNS delivery for nootropic effects. Formal human pharmacokinetic studies of intranasal Semax are not published, but the route is presumed to provide efficient CNS penetration based on observed clinical effects.

Pharmacokinetics

Published pharmacokinetic data in humans is limited. Preclinical studies suggest Semax has a relatively short plasma half-life (estimated at 30-40 minutes based on animal studies), but human PK data is not available in published literature. The short apparent plasma half-life contrasts with the apparent long duration of pharmacodynamic effects (cognitive benefits persist for hours to days after single doses), suggesting that Semax's effects on BDNF, neuroplasticity, and dopamine systems persist after the peptide has been cleared from circulation. This supports once or twice-daily dosing despite apparent short half-life.

Side Effects and Safety Profile

Notable Safety Advantages

No adrenal side effects: Unlike ACTH, Semax does not activate the adrenal cortex. No elevated cortisol or hormonal side effects have been documented.

No abuse potential or dependence: Semax does not produce euphoria or physical dependence. It can be discontinued without withdrawal effects.

No cognitive impairment: Unlike stimulant medications, Semax does not produce jitteriness, anxiety, or overstimulation at studied doses.

Long-Term Safety Data

Post-marketing surveillance in Russia extends to years of use in chronic stroke and cognitive disorder populations. This data supports that Semax can be used chronically without documented complications or tolerance development.

Semax vs. Selank: Complementary Peptides

While both Semax and Selank are Russian-developed peptides approved for clinical use in Russia, they represent fundamentally different therapeutic approaches and should be understood as complementary rather than competitive peptides:

Primary Clinical Indication

Semax: Neurological and cognitive (stroke, cognitive disorders, ADHD, neuroprotection)

Selank: Psychiatric and anxiety (anxiety disorders, stress adaptation)

Primary Mechanism

Semax: BDNF/NGF upregulation, neuroplasticity enhancement, dopamine modulation

Selank: GABA and serotonin modulation, BDNF enhancement, immunomodulation

Pharmacological Profile

Semax: "Activating",enhances cognitive function, alertness, and executive function

Selank: "Calming",reduces anxiety and promotes relaxation without sedation

Effect on Mood and Cognition

Semax: Enhances cognition and attention; may support mood through dopamine and BDNF mechanisms but is not primarily an antidepressant

Selank: Reduces anxiety and may support mood through serotonin mechanisms; cognitive enhancement is secondary to anxiety reduction

Immunological Effects

Semax: No immunomodulatory component; not designed for immune effects

Selank: Contains tuftsin-derived immunomodulatory component enhancing macrophage/neutrophil function

Hormonal Effects

Semax: Derived from ACTH but does NOT activate adrenal function; no hormonal side effects despite peptide structure

Selank: No hormonal component or effects; pure neuropsychotropic peptide

Potential Stacking Rationale

While no published studies examine Semax+Selank combination, theoretical stacking rationale would be complementary effects: Semax "activating" cognition and attention, Selank "calming" anxiety and stress response. In theory, this combination could provide both cognitive enhancement and anxiety reduction in a single regimen. However, this remains entirely theoretical without published evidence.

Practical Distinction

Semax and Selank represent different solutions to different problems: Semax for patients seeking cognitive enhancement and neuroprotection, Selank for patients seeking anxiety reduction. They are not substitutes for one another but rather complementary peptides addressing distinct physiological systems and clinical needs.

Frequently Asked Questions